Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General Anesthesia

Phase 3

Completed

Conditions: General Anesthesia

Interventions: Drug: HSK3486
Drug: Propofol

Registration Number: NCT05478174

Lead Sponsor: Haisco-USA Pharmaceuticals, Inc.

Brief Summary: To demonstrate HSK3486 0.4/0.2 mg/kg (0.4 mg/kg intravenous \[IV\] slow injection over 30 \[±5\] seconds for the first dose, an additional 0.2 mg/kg if needed) is non-inferior to propofol 2.0/1.0 mg/kg (2.0 mg/kg IV slow injection over 30 \[±5\] seconds for first dose, an additional 1.0 mg/kg if needed) in success of induction of general anesthesia in adults undergoing elective surgery.

Detailed Description: This is a multicenter, randomized, double-blinded, propofol-controlled, phase 3 clinical study to evaluate the efficacy and safety of HSK3486 for induction of general anesthesia in adults undergoing elective surgery with endotracheal intubation.

After screening, eligible subjects will be randomized in a 2:1 ratio to receive either HSK3486 0.4/0.2 mg/kg (i.e., 0.4 mg/kg IV slow injection over 30 \[±5\] seconds followed by an additional 0.2 mg/kg dose over 10 \[±2\] seconds if needed) or propofol 2.0/1.0 mg/kg (i.e., 2.0 mg/kg IV slow injection over 30 \[±5\] seconds followed by an additional 1.0 mg/kg dose over 10 \[±2\]seconds if needed) in a blinded manner. Enrolled subjects will be stratified by American Society of Anesthesiologists Physical Status (ASA-PS; I-II and III-IV), age (\<65 and ≥65 years), and Body Mass Index (BMI \<35 and ≥35 kg/m2). Endotracheal intubation will be performed after adequate anesthetic induction (Modified Observer's Assessment of Awareness/Sedation \[MOAA/S\] ≤1) (Appendix 1) has been achieved and administration of neuromuscular blocking agent.

Before surgery, premedication is allowed except for sedative-hypnotic or analgesic drugs. Premedication should be recorded if used.

Prior to administration of the study drug in the operating room, the preoperative readiness of each subject will be confirmed. Oxygen will be supplied through a facemask (oxygen flow rate: ≥4 L/min) at least 2 minutes before study drug administration. Subsequently, the investigator can adjust the oxygen flow according to the specific situation of the subject and maintenance IV solution (normal saline \[NS\], lactated ringer's \[LR\], or 5% dextrose) will be administrated through IV infusion. Throughout the preinduction and induction periods, a timing device must be used to allow accuracy and sequencing of necessary assessments.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 400

Inclusion Criteria

1. Subjects undergoing elective surgery (non emergency, non cardiothoracic, and non intracranial surgery, anticipated to last at least 1 hour) requiring endotracheal intubation and inhalation general anesthesia during the maintenance period. Duration of surgery is defined as time from study drug administration to time of transfer from operating room to recovery room or PACU.
2. Males or females, aged ≥18 years old, with ASA-PS I to IV (Appendix 6). For ASA-PS IV subjects, clinical status must be optimized at time of preoperative anesthesia evaluation per judgement of the anesthesiologist.
3. BMI ≥18 kg/m2. 4. Vital signs at screening: RR ≥10 and ≤24 breaths/min; SpO2≥92% in ambient air; SBP ≥90 and ≤160 mmHg; DBP ≥55 and ≤100 mmHg; HR ≥55 (or ≥50 if subjects are on beta blockers) and ≤100 beats/min.
4. For all women of childbearing potential, negative serum pregnancy test at screening and must have negative urine pregnancy test at baseline (Day 1). Additionally, women of childbearing potential* must agree to use effective contraception as defined in 7.3.4 from the time of consent until 30 days post study drug administration.
5. Capable of understanding the procedures and methods of this study, willing to sign an Informed Consent Form, and able to complete this study in strict compliance with the study protocol.
6. Willing to comply with the site's COVID guidelines and testing requirements as applicable.
7. Patients with psychiatric/mental disorders must be considered stable on treatment (e.g., SSRIs, SNRIs, TCAs, MAOIs, psychotherapy) and no hospitalizations and urgent care for at least 1 year.
*Women NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral salpingo-oophorectomy) or who are postmenopausal (defined 12 months since last regular menses).

Exclusion criteria:

Contraindications to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subject having contraindications to propofol, opioids, and their antidotes.
Medical condition or evidence of increased sedation/general anesthesia risk as follows:
1. Cardiovascular disorders: uncontrolled hypertension (SBP>160 mmHg and/or DBP >100 mmHg) with or without antihypertensive therapy (antihypertensive therapy should be stable for 1 month prior to screening), serious arrhythmia (including the subjects with implanted pace makers), unstable heart failure, Adams-Stokes syndrome (i.e., syncope or near syncope due to cardiac arrythmia), unstable angina, myocardial infarction occurring within 6 months prior to screening, history of tachycardia/bradycardia requiring medications, third degree atrioventricular block or QT interval corrected for HR using Fridericia's formula (QTcF)≥450ms for males and ≥470ms for females.
2. History of severe obstructive lung disease (i.e., forced expiratory volume in 1 second [FEV1] <50% predicted), history of bronchospasm requiring treatment in a hospital emergency room or hospitalization occurring within 3 months prior to screening, developing acute respiratory tract infection within 2 weeks prior to baseline (such as symptoms of fever, shortness of breath, wheezing, nasal congestion, and cough).
3. Cerebrovascular disease: subject with a history of serious craniocerebral injury, convulsion, seizure disorder, intracranial hypertension, cerebral aneurysm, or stroke.
4. Patients with psychiatric diseases (schizophrenia, mania) who have not been on a stable treatment regimen (with SSRIs, SNRIs, TCAs, MAOIs) for at least 1 year or who have been hospitalized or had emergent/urgent care within the past year.
5. Uncontrolled clinically significant conditions of liver (e.g., severe hepatic insufficiency defined as Childs-Pugh class C), kidney, gastrointestinal tract, blood system, nervous system, or metabolic system diseases, judged by the investigator to be unsuitable for involvement in the study.
6. Known glycosylated hemoglobin (HbA1c) greater than or equal to 10%.
7. Known thyroid-stimulating hormone (TSH) value 10% outside the normal range or on thyroid replacement therapy with a known free T-4 level outside the normal range.
8. History of alcohol abuse within 3 months prior to screening, where alcohol abuse refers to daily alcohol drinking >2 units (1 unit = 360 mL of beer or 45 mL of spirit with a strength of 40% or 150 mL of wine).
9. History of drug abuse that, in the opinion of the investigator, may confound the interpretation of safety or efficacy in a study subject.
Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study as follows:
1. Asthma must be stable: stable doses of asthma medications for the past 6 months, no requirement for rescue inhalers or oral steroids within past 6 months, not evaluated in emergency department, urgent care, or hospitalized for an asthma attack within past 1 year.
2. History (or family history) of malignant hyperthermia.
3. Any previous failure of tracheal intubation.
4. Judged to have a difficult airway for endotracheal intubation in the opinion of the Investigator based on parameters such as modified Mallampati score (Grade III or IV [Appendix 7], neck mobility, short thyromental distance, and/or history of difficult intubation).
Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics (e.g., benzodiazepines and opioids) taken within 5 half-lives prior to Day 1.
Laboratory parameters measured at screening with the following levels:
1. Neutrophil count ≤1.5 x 109/L
2. Platelet count <80 x 109/L
3. Hemoglobin <90 g/L (without blood transfusion within 14 days)
4. Alanine transaminase and/or aspartate transaminase ≥2.0 x upper limit of normal (ULN)
5. Total bilirubin ≥2.0 x ULN
6. Severe renal impairment defined by creatinine clearance (CrCl) ≤30 mL/min
Female subjects with a positive pregnancy test at screening (serum) or baseline (urine); lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.

Exclusion Criteria

Not provided

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
HSK3486	HSK3486	HSK3486 for general anesthesia induction
Propofol	Propofol	Propofol for general anesthesia induction

Primary Outcome Measures

Name	Time	Method
Success Rate of General Anesthesia Induction	From the time of study drug administration to desired depth of anesthesia to MOAA/S≤1 ( up to 5 minutes)	1. Induction success (MOAA/S ≤1) after administration of the study drug, and 2. One or less top-up doses required without using any rescue drugs.

Secondary Outcome Measures

Name	Time	Method
Percentage of Subjects With Successful Induction Who Maintain the Desired Depth of Anesthesia for General Elective Surgery, AND Without Significant Cardiac and Respiratory Depression	15 minutes from end of drug administration	The outcome is defined by all the following conditions: a) Desired depth of anesthesia for general elective surgery is defined if all following criteria are met: i) No clinical signs of inadequate depth of anesthesia, such as lacrimation, movement, vomiting, coughing, laryngospasm, bucking, swallowing reflex or bronchospasm etc. ii) No blood pressure (SBP, DBP, or MAP) increases more than 20% from baseline in response to any major operational procedures or noxious stimulus in defined period. iii) Subjects maintain desired depth of anesthesia for general elective surgery with BIS as an objective assessment (after reaching initial lowest value, BIS remains sustainable level at not more than 60). b) No significant respiratory depression, such as apnea, prior to the administration of rocuronium bromide. c) No significant cardiac depression indicated by blood pressure decrease that requires intervention, i.e., vasopressors and/or IV fluid resuscitation.
Percentage of Subjects With Any Injection-site Pain on Numeric Rating Scale ≥1	From start of drug administration to MOAA/S ≤1 (up to 3 minutes)	0 = No Pain 1-3 = Mild Pain 4-6 = Moderate Pain 7-9 = Severe Pain 10 = Worst pain imaginable

Trial Locations

Locations (23): Phoenix Clinical Research
🇺🇸
Tamarac, Florida, United States
Chesapeake Research Group, Llc
🇺🇸
Pasadena, Maryland, United States
The Ohio State University Wexner Medical Center
🇺🇸
Columbus, Ohio, United States
Coastal Clinical Research Specialists
🇺🇸
Jacksonville, Florida, United States
NextStage Clinical Research - Abay Neuroscience Center
🇺🇸
Wichita, Kansas, United States
HD Research
🇺🇸
Bellaire, Texas, United States
Hd Research Llc.
🇺🇸
Carrollton, Texas, United States
Gulfcoast Research Institute, Llc
🇺🇸
Sarasota, Florida, United States
Brigham & Women'S Hospital
🇺🇸
Boston, Massachusetts, United States
The University of Texas - MD Anderson Cancer Center
🇺🇸
Houston, Texas, United States
Arizona Research Center
🇺🇸
Phoenix, Arizona, United States
University of Miami Hospital
🇺🇸
Miami, Florida, United States
Duke University Health
🇺🇸
Durham, North Carolina, United States
Oregon Health & Science University
🇺🇸
Portland, Oregon, United States
Urology San Antonio Research
🇺🇸
San Antonio, Texas, United States
Endeavor Clinical Trials
🇺🇸
San Antonio, Texas, United States
Jbr Clinical Research
🇺🇸
Salt Lake City, Utah, United States
UC Davis Health
🇺🇸
Davis, California, United States
Shoals Medical Trials, Inc.
🇺🇸
Sheffield, Alabama, United States
Rush University Medical Center
🇺🇸
Chicago, Illinois, United States
ForCare Clinical Research
🇺🇸
Tampa, Florida, United States
Midwest Clinical Research Center
🇺🇸
Dayton, Ohio, United States
University Hospitals Cleveland Medical Center
🇺🇸
Cleveland, Ohio, United States